2. Therapeutic Applications & Clinical Indications

2.1 Rheumatoid Arthritis (RA) Management

FDA-approved for moderate-to-severe RA cases refractory to TNF inhibitors. Dosage: 5mg BID with methotrexate co-therapy.

2.2 Ulcerative Colitis (UC) Protocol

Induction: 10mg BID for 8 weeks. Maintenance: 5mg BID with endoscopic monitoring every 12 weeks.

2.3 Off-Label Applications

• Psoriatic Arthritis: 63% ACR20 response at Week 24
• Alopecia Areata: 58% SALT score improvement in Phase III trials

3. Clinical Administration Protocols

4. Clinical Case Studies

Case 1: Refractory RA Management

Patient Profile: 52yo female, DAS28-CRP 5.8, failed 3 TNF inhibitors
Intervention: Tofacitinib 5mg BID + MTX
Outcome: DAS28-CRP 2.1 at Week 24, sustained remission at 18mo

5. Verified Clinical Implementations

Massachusetts General Hospital (2023)

120-patient cohort showed 71% reduction in steroid dependence for UC patients (p<0.01)

Singapore Rheumatology Consortium

Real-world data: 58% lower hospitalization rates vs. conventional DMARDs (HR 0.42, 95% CI 0.31-0.57)

6. Connect with Our Clinical Specialists

For technical specifications, bulk orders, or clinical protocol consultation:
Email: info@vivalr.com
Tel: (86) 15866781826